Skip to content

Citius Pharmaceuticals, Inc.: 10-K filed 2018-12-11

What Citius Pharmaceuticals, Inc. reported in its annual report filed 2018-12-11 (fiscal FY 2018): 28 published measures, 73 facts as tagged in accession 0001213900-18-017214.

This filing

Form
10-K (annual report)
Filed
2018-12-11
Fiscal period
fiscal FY 2018
Accession
0001213900-18-017214 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-09-3031,050,524USD
At 2017-09-3024,416,553USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-09-3027,865,684USD
At 2017-09-3021,947,388USD
At 2016-09-3016,766,383USD
At 2015-09-30-635,213USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-09-309,184,003USD
At 2017-09-303,204,108USD
At 2016-09-30294,351USD
At 2015-09-30676,137USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-10-01 to 2018-09-30-12,536,638USD365
2016-10-01 to 2017-09-30-10,384,953USD365
2015-10-01 to 2016-09-30-8,295,698USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-10-01 to 2018-09-30-11,318,138USD365
2016-10-01 to 2017-09-30-7,971,205USD365
2015-10-01 to 2016-09-30-5,900,421USD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-10-01 to 2017-09-302,126USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-10-01 to 2018-09-3017,298,033USD365
2016-10-01 to 2017-09-3010,883,088USD365
2015-10-01 to 2016-09-305,262,887USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-10-01 to 2017-09-30-2,126USD365
2015-10-01 to 2016-09-30255,748USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-09-30-40,257,838USD
At 2017-09-30-27,721,200USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-09-301,483USD
At 2017-09-303,236USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-10-01 to 2018-09-30779,701USD365
2016-10-01 to 2017-09-30986,620USD365
2015-10-01 to 2016-09-30732,151USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-10-01 to 2018-09-30-13,789,143USD365
2016-10-01 to 2017-09-30-9,986,311USD365
2015-10-01 to 2016-09-30-7,449,291USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-09-3010,060,078USD
At 2017-09-303,424,354USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-10-01 to 2018-09-3015,838USD365
2016-10-01 to 2017-09-30850,789USD365
2015-10-01 to 2016-09-308,994USD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-09-303,184,840USD
At 2017-09-302,469,165USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-09-301,573,444USD
At 2017-09-30602,431USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2018-09-301,586,796USD
At 2017-09-301,586,796USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-10-01 to 2018-09-3013,789,143USD365
2016-10-01 to 2017-09-309,986,311USD365
2015-10-01 to 2016-09-307,449,291USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-10-01 to 2018-09-306,562,925USD365
2016-10-01 to 2017-09-302,936,252USD365
2015-10-01 to 2016-09-302,933,199USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-09-3016,198,791shares
At 2017-09-308,345,844shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-09-3068,107,323USD
At 2017-09-3049,660,242USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-09-30181,657USD
At 2017-09-30560,918USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2017-10-01 to 2018-09-30-12,536,638USD365
2016-10-01 to 2017-09-30-10,384,953USD365
2015-10-01 to 2016-09-30-8,295,698USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-10-01 to 2018-09-306,446,517USD365
2016-10-01 to 2017-09-306,063,439USD365
2015-10-01 to 2016-09-303,783,941USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-10-01 to 2018-09-301,753USD365
2016-10-01 to 2017-09-302,632USD365
2015-10-01 to 2016-09-301,343USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-10-01 to 2018-09-301,252,505USD365
2016-10-01 to 2017-09-30-398,642USD365
2015-10-01 to 2016-09-30-846,407USD366

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2017-10-01 to 2018-09-30193USD365
2016-10-01 to 2017-09-301,133USD365
2015-10-01 to 2016-09-301,985USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-10-01 to 2018-09-30971,013USD365
2016-10-01 to 2017-09-30-306,725USD365
2015-10-01 to 2016-09-30105,230USD366

Inspect the source

Entity
Citius Pharmaceuticals, Inc. / CIK 0001506251
Captured
2026-09-20T09:12:24.553Z
SEC response SHA-256
dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))